{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T00:55:20Z","timestamp":1748134520504,"version":"3.40.5"},"reference-count":18,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","ajconline.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.amjcard.2017.06.042","type":"journal-article","created":{"date-parts":[[2017,7,18]],"date-time":"2017-07-18T03:15:54Z","timestamp":1500347754000},"page":"1043-1048","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from CHAMPION PHOENIX)"],"prefix":"10.1016","volume":"120","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0885-1953","authenticated-orcid":false,"given":"Muthiah","family":"Vaduganathan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregg W.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ph Gabriel","family":"Steg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Michael","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian W.","family":"Hamm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew J.","family":"Price","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Efthymios N.","family":"Deliargyris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jayne","family":"Prats","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth W.","family":"Mahaffey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harvey D.","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2017.06.042_bib0010","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa0908629","article-title":"Intravenous platelet blockade with cangrelor during PCI","volume":"361","author":"Bhatt","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2017.06.042_bib0015","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1056\/NEJMoa0908628","article-title":"Platelet inhibition with cangrelor in patients undergoing PCI","volume":"361","author":"Harrington","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2017.06.042_bib0020","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","article-title":"Effect of platelet inhibition with cangrelor during PCI on ischemic events","volume":"368","author":"Bhatt","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2017.06.042_bib0025","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/S0140-6736(13)61615-3","article-title":"Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data","volume":"382","author":"Steg","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2017.06.042_bib0030","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jacc.2016.11.017","article-title":"Cangrelor use since FDA approval: a single-center, real-world experience at a tertiary care hospital","volume":"69","author":"Vaduganathan","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2017.06.042_bib0035","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1016\/j.jcin.2016.09.020","article-title":"Use and effectiveness of bivalirudin versus unfractionated heparin for percutaneous coronary intervention among patients with ST-segment elevation myocardial infarction in the United States","volume":"9","author":"Secemsky","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.amjcard.2017.06.042_bib0040","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.ahj.2012.02.018","article-title":"Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial","volume":"163","author":"Leonardi","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2017.06.042_bib0050","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.jacc.2015.11.027","article-title":"Investigator-reported bleeding versus post hoc adjudication of bleeding: lessons from the CHAMPION PHOENIX trial","volume":"67","author":"Jatene","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2017.06.042_bib0055","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1016\/j.jacc.2012.11.019","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"61","author":"O'Gara","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2017.06.042_bib0060","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1016\/j.jacc.2011.08.007","article-title":"2011 ACCF\/AHA\/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions","volume":"58","author":"Levine","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2017.06.042_bib0065","doi-asserted-by":"crossref","first-page":"e003612","DOI":"10.1161\/CIRCINTERVENTIONS.116.003612","article-title":"Variation in patient profiles and outcomes in US and non-US subgroups of the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) PHOENIX Trial","volume":"9","author":"Vaduganathan","year":"2016","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.amjcard.2017.06.042_bib0070","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.jcin.2014.09.025","article-title":"Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (a clinical trial comparing cangrelor to clopidogrel standard therapy in subjects who require percutaneous coronary intervention [PCI])","volume":"8","author":"White","year":"2015","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.amjcard.2017.06.042_bib0075","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1093\/eurheartj\/ehu223","article-title":"Balancing the risks of stent thrombosis and major bleeding during primary percutaneous coronary intervention","volume":"35","author":"Gutierrez","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2017.06.042_bib0080","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1001\/jamacardio.2016.4556","article-title":"Evaluation of ischemic and bleeding risks associated with 2 parenteral antiplatelet strategies comparing cangrelor with glycoprotein IIb\/IIIa inhibitors: an exploratory analysis from the CHAMPION Trials","volume":"2","author":"Vaduganathan","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.amjcard.2017.06.042_bib0085","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jacc.2016.10.055","article-title":"Cangrelor with and without glycoprotein IIb\/IIIa inhibitors in patients undergoing percutaneous coronary intervention","volume":"69","author":"Vaduganathan","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2017.06.042_bib0090","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1093\/eurheartj\/ehv498","article-title":"The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX","volume":"37","author":"Gutierrez","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2017.06.042_bib0095","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/HPC.0000000000000098","article-title":"An updated protocol for evaluating chest pain and managing acute coronary syndromes","volume":"16","author":"Kelly","year":"2017","journal-title":"Crit Pathw Cardiol"},{"key":"10.1016\/j.amjcard.2017.06.042_bib0100","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.amjcard.2003.08.063","article-title":"Revisiting optimal anticoagulation with unfractionated heparin during coronary stent implantation","volume":"92","author":"Brener","year":"2003","journal-title":"Am J Cardiol"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914917311049?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914917311049?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T00:57:15Z","timestamp":1535590635000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914917311049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0002914917311049"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2017.06.042","relation":{},"ISSN":["0002-9149"],"issn-type":[{"type":"print","value":"0002-9149"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from CHAMPION PHOENIX)","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2017.06.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}